Format

Send to

Choose Destination
Ann Lab Med. 2019 Nov;39(6):530-536. doi: 10.3343/alm.2019.39.6.530.

Application of the Whole Genome-Based Bacterial Identification System, TrueBac ID, Using Clinical Isolates That Were Not Identified With Three Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Systems.

Ha SM#1,2, Kim CK#3,4, Roh J5, Byun JH4,5,6, Yang SJ1, Choi SB1, Chun J1,2, Yong D4,5,7.

Author information

1
ChunLab, Inc., Seoul, Korea.
2
School of Biological Sciences & Institute of Molecular Biology and Genetics, Seoul National University, Seoul, Korea.
3
Seoul Clinical Laboratories, Yongin, Korea.
4
Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea.
5
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.
6
Department of Laboratory Medicine, Gyeongsang National University Hospital, and Gyeongsang National University College of Medicine, Jinju, Korea.
7
Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea. deyong@yuhs.ac.
#
Contributed equally

Abstract

BACKGROUND:

Next-generation sequencing is increasingly used for taxonomic identification of pathogenic bacterial isolates. We evaluated the performance of a newly introduced whole genome-based bacterial identification system, TrueBac ID (ChunLab Inc., Seoul, Korea), using clinical isolates that were not identified by three matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) systems and 16S rRNA gene sequencing.

METHODS:

Thirty-six bacterial isolates were selected from a university-affiliated hospital and a commercial clinical laboratory. Species was identified by three MALDI-TOF MS systems: Bruker Biotyper MS (Bruker Daltonics, Billerica, MA, USA), VITEK MS (bioMérieux, Marcy l'Étoile, France), and ASTA MicroIDSys (ASTA Inc., Suwon, Korea). Whole genome sequencing was conducted using the Illumina MiSeq system (Illumina, San Diego, CA, USA), and genome-based identification was performed using the TrueBac ID cloud system (www.truebacid.com).

RESULTS:

TrueBac ID assigned 94% (34/36) of the isolates to known (N=25) or novel (N=4) species, genomospecies (N=3), or species group (N=2). The remaining two were identified at the genus level.

CONCLUSIONS:

TrueBac ID successfully identified the majority of isolates that MALDI-TOF MS failed to identify. Genome-based identification can be a useful tool in clinical laboratories, with its superior accuracy and database-driven operations.

KEYWORDS:

Genome-based identification; Next generation sequencing; Performance; TrueBac ID

PMID:
31240880
PMCID:
PMC6660342
DOI:
10.3343/alm.2019.39.6.530
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for The Korean Society for Laboratory Medicine Icon for PubMed Central
Loading ...
Support Center